Drug Protocol Field Directory

An irreversible cyclooxygenase-1 (COX-1) inhibitor that permanently halts platelet thromboxane A2 synthesis, preventing progressive occlusive thrombus propagation in acute coronary syndromes and ischemic heart disease.

An oral gastrointestinal adsorbent with an enormous porous surface area that binds ingested xenobiotics, preventing enteral absorption and truncating enterohepatic recirculation.

An ultra-short-acting endogenous purine nucleoside that transiently blocks AV nodal conduction to terminate paroxysmal supraventricular tachycardias.

A non-selective endogenous catecholamine that exerts potent direct alpha-1, beta-1, and beta-2 adrenergic receptor stimulation to restore coronary perfusion in arrest, reverse bronchospasm, and stabilize catastrophic anaphylactic shock.

A broad-spectrum Class III antiarrhythmic multichannel blocker with non-competitive alpha- and beta-blocking properties that prolongs cardiac action potential duration and refractoriness to terminate shock-refractory VF and stable wide-complex tachycardias.

A prototypical tertiary amine antimuscarinic agent that competitively blocks acetylcholine at post-ganglionic parasympathetic muscarinic receptors to accelerate sinoatrial nodal automaticity in unstable bradycardia and halt fatal bronchorrhea in organophosphate poisoning.

A potent fluorinated synthetic glucocorticoid that crosses the placenta to induce fetal pulmonary surfactant synthesis and accelerate lung maturation in threatened preterm delivery.

An essential parenteral electrolyte solution that provides immediate cardiac membrane stabilization against hyperkalemia and reverses calcium channel blocker toxicity.

A second-generation thienopyridine prodrug that irreversibly blocks platelet P2Y12 ADP receptors to inhibit arterial platelet aggregation in acute STEMI and NSTE-ACS.

A multi-modal toxicological antidote complex combining Hydroxocobalamin, Sodium Nitrite, and Sodium Thiosulfate that scavenges cyanide and reactivates mitochondrial cellular respiration.

A first-generation piperazine histamine H1 receptor antagonist with central anticholinergic and antiemetic properties, targeting the chemoreceptor trigger zone and vestibular pathway.

A hypertonic carbohydrate solution that immediately elevates serum glucose concentrations to reverse neuroglycopenic coma, seizures, and acute hypoglycemia.

A long-acting benzodiazepine anticonvulsant and anxiolytic that enhances GABA-A receptor chloride conductance to terminate prolonged generalized seizures.

A synthetic sympathomimetic inotrope with potent Beta-1 receptor agonism that enhances myocardial contractility and stroke volume while reducing ventricular filling pressures in cardiogenic shock.

A dose-dependent endogenous catecholamine inotrope, chronotrope, and vasopressor stimulating dopaminergic, beta-1, and alpha-1 adrenergic receptors in cardiogenic and septic shock.

A low-molecular-weight heparin (LMWH) with high anti-Factor Xa to anti-Factor IIa activity, serving as essential antithrombin co-therapy in STEMI fibrinolysis and acute coronary syndromes.

A rapid-acting non-barbiturate carboxylated imidazole induction hypnotic that provides profound anesthesia with exceptional hemodynamic stability during emergency RSI.

A rapid-acting, short-acting Beta-2 adrenergic receptor agonist (SABA) delivering potent bronchodilation and relief of acute bronchospasm in asthma and COPD.

A synthetic phenylpiperidine opioid agonist approximately 100 times more potent than morphine that produces rapid, hemodynamically stable analgesia without histamine release, but carries high risk of wooden chest syndrome if pushed rapidly.

A specific imidazobenzodiazepine competitive antagonist at the central GABA-A receptor complex, selectively reversing benzodiazepine sedation and respiratory depression.

A potent loop diuretic that inhibits the Na+/K+/2Cl- co-transporter in the thick ascending limb of Henle and induces rapid systemic venodilation to relieve acute cardiogenic pulmonary edema.

A recombinant peptide hormone that stimulates hepatic glycogenolysis to reverse severe hypoglycemia when IV access is impossible, and acts as a non-adrenergic inotrope in beta-blocker overdose.

An organic nitrate prodrug that undergoes enzymatic denitration to release nitric oxide, stimulating guanylyl cyclase to induce potent systemic venodilation and coronary artery dilatation, drastically reducing cardiac preload in acute angina and pulmonary edema.

An unfractionated glycosaminoglycan anticoagulant that potently accelerates Antithrombin III, inactivating thrombin and Factor Xa in acute STEMI PCI transfer and massive pulmonary embolism.

A direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, reducing systemic vascular resistance and lowering severe blood pressure in pre-eclamptic hypertensive emergencies.

A short-acting parenteral systemic glucocorticoid that inhibits inflammatory cascades and stabilizes capillary permeability in severe anaphylaxis, status asthmaticus, and adrenal crisis.

A quaternary ammonium antispasmodic that competitively antagonizes muscarinic receptors in gastrointestinal, biliary, and genitourinary smooth muscle, relieving acute colic.

A propionic acid non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2 enzymes to decrease prostaglandin synthesis in acute inflammatory pain.

An anticholinergic bronchodilator that blocks muscarinic receptors on bronchial smooth muscle to reduce bronchospasm and dry excessive secretions.

A long-acting organic nitrate vasodilator and nitric oxide donor that dilates venous capacitance beds and coronary arteries, dramatically reducing preload in acute pulmonary edema.

A rapid-acting dissociative anesthetic and potent analgesic that disrupts sensory perception and pain signaling while stimulating sympathetic tone to preserve blood pressure and spontaneous respiration.

A combined selective Alpha-1 and non-selective Beta-1/Beta-2 adrenergic receptor blocker that reduces systemic vascular resistance without precipitating reflex tachycardia.

A Class Ib antiarrhythmic and amide local anesthetic that blocks voltage-gated fast sodium channels to suppress ventricular ectopy and numb intraosseous medullary channels.

A potent intermediate-acting benzodiazepine that enhances GABA-A receptor chloride conductance, serving as the first-line anticonvulsant for status epilepticus and severe violent agitation.

A physiological divalent cation that acts as an endogenous calcium antagonist and NMDA blocker to suppress eclamptic convulsions, relax bronchial smooth muscle in life-threatening asthma, and terminate polymorphic VT (Torsades de Pointes).

An essential therapeutic compressed gas providing vital cellular oxygenation to halt anaerobic metabolism and prevent ischemic end-organ failure in acute hypoxemia and shock.

A rapidly acting, self-administered inhaled volatile fluorinated hydrocarbon analgesic delivered via the Penthrox inhaler for moderate to severe traumatic pain.

An intermediate-acting synthetic glucocorticoid with potent genomic and non-genomic anti-inflammatory activity, reversing airway mucosal edema and blunting cytokine cascades.

A prokinetic dopamine D2 antagonist and antiemetic that accelerates upper GI motility and blocks chemoreceptor trigger zone emetic signaling.

A rapid-acting, water-soluble imidazobenzodiazepine that acts as a positive allosteric modulator at central GABA-A receptors, delivering potent anticonvulsant, amnestic, and sedative effects for status epilepticus and emergency procedural sedation.

A prototypical natural phenanthrene alkaloid opioid that binds stereospecifically to central and spinal mu-opioid receptors to attenuate nociceptive transmission, alleviate severe acute pain, and reduce cardiac preload in acute pulmonary edema.

A pure competitive opioid receptor antagonist with high affinity for mu-opioid receptors that displaces opioids to rapidly reverse life-threatening opioid-induced respiratory depression and coma.

A reversible anticholinesterase quaternary amine that elevates acetylcholine concentrations at the neuromuscular junction to reverse non-depolarizing neuromuscular blockade.

A dihydropyridine L-type calcium channel blocker delivering selective peripheral arteriolar vasodilation to lower severe blood pressure in pre-eclampsia and tocolyze preterm labor.

An inhaled premixed 50:50 medical gas providing rapid, self-administered analgesic and mild anxiolytic effects for acute pain in trauma, burns, and labor.

A highly selective 5-HT3 serotonin receptor antagonist delivering potent, non-sedating antiemesis without extrapyramidal side effects, indicated for severe nausea and vomiting.

A synthetic nonapeptide hormone that stimulates uterine smooth muscle oxytocin receptors to induce rhythmic contractions and prevent fatal postpartum hemorrhage (PPH).

An intravenous and oral non-opioid central analgesic and antipyretic acting via central cyclooxygenase inhibition and cannabinoid/TRPV1 receptor modulation.

An oral intermediate-acting synthetic glucocorticoid that suppresses inflammatory cascades, reduces mucosal edema, and halts late-phase bronchoconstriction in asthma and croup.

A first-generation phenothiazine antihistamine, antiemetic, and sedative acting as a potent competitive H1 and muscarinic antagonist.

An intermediate-acting non-depolarizing aminosteroid neuromuscular blocker that competitively antagonizes nicotinic acetylcholine receptors at the motor endplate, providing rapid, safe skeletal muscle flaccidity for emergency endotracheal intubation.

A short-acting selective beta-2 adrenergic agonist that stimulates adenylyl cyclase to increase cyclic AMP in bronchial smooth muscle, triggering rapid bronchodilation in severe asthma/COPD and shifting potassium intracellularly in hyperkalemia.

A hypertonic alkalinizing agent that unbinds tricyclic antidepressants from myocardial fast sodium channels and drives intracellular potassium shifting in severe metabolic acidosis.

A unique dual-action Class III antiarrhythmic and non-selective Beta-blocker that prolongs cardiac action potential duration and refractoriness to terminate tachyarrhythmias.

A bacterial plasminogen activator that forms an active stoichiometric complex to generate plasmin, dissolving coronary and pulmonary intravascular fibrin thrombi.

A modified gamma-cyclodextrin selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium, achieving instant reversal in 'cannot intubate, cannot oxygenate' crises.

An ultra-rapid, short-acting depolarizing neuromuscular blocker composed of two linked acetylcholine molecules that produces immediate motor endplate depolarization and profound flaccidity within 45 seconds for emergency RSI.

A third-generation bio-engineered recombinant fibrinolytic agent administered as a single weight-adjusted IV bolus for pre-hospital STEMI reperfusion.

An essential water-soluble B-complex vitamin cofactor (Vitamin B1) mandatory before or alongside IV dextrose to prevent precipitating acute Wernicke-Korsakoff encephalopathy.

A synthetic lysine analogue antifibrinolytic that competitively blocks plasminogen activation to preserve forming blood clots, preventing catastrophic exsanguination in severe polytrauma and postpartum hemorrhage.

An intermediate-acting aminosteroid non-depolarizing neuromuscular blocker that competitively antagonizes nicotinic acetylcholine receptors, providing muscle relaxation for mechanical ventilation.